Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Monday. The brokerage presently has a $82.00 price target on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 6.85% from the company’s previous close.
According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
Several other equities analysts have also recently issued reports on ENTA. BidaskClub cut Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. JPMorgan Chase & Co. cut Enanta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Thursday. Royal Bank of Canada lifted their price target on Enanta Pharmaceuticals to $78.00 and gave the company a “sector perform” rating in a research report on Thursday. Finally, TheStreet upgraded Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Wednesday, December 13th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $57.40.
Shares of Enanta Pharmaceuticals (ENTA) traded up $3.32 during mid-day trading on Monday, hitting $76.74. The stock had a trading volume of 365,989 shares, compared to its average volume of 230,467. Enanta Pharmaceuticals has a one year low of $27.24 and a one year high of $95.91. The firm has a market cap of $1,470.00, a PE ratio of 46.51 and a beta of 1.04.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, November 20th. The biotechnology company reported $1.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.13 by ($0.27). Enanta Pharmaceuticals had a net margin of 26.35% and a return on equity of 13.33%. The firm had revenue of $75.93 million for the quarter, compared to analyst estimates of $73.80 million. During the same quarter last year, the business posted ($0.09) earnings per share. The firm’s revenue for the quarter was up 491.3% compared to the same quarter last year. equities research analysts predict that Enanta Pharmaceuticals will post 0.86 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of ENTA. East Coast Asset Management LLC. acquired a new position in shares of Enanta Pharmaceuticals in the 4th quarter worth $218,000. LS Investment Advisors LLC grew its holdings in shares of Enanta Pharmaceuticals by 56.8% in the 4th quarter. LS Investment Advisors LLC now owns 3,714 shares of the biotechnology company’s stock worth $218,000 after acquiring an additional 1,345 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in shares of Enanta Pharmaceuticals in the 3rd quarter worth $220,000. Hartland & Co. LLC acquired a new position in shares of Enanta Pharmaceuticals in the 3rd quarter worth $237,000. Finally, UBS Asset Management Americas Inc. acquired a new position in shares of Enanta Pharmaceuticals in the 4th quarter worth $241,000. Institutional investors and hedge funds own 68.04% of the company’s stock.
WARNING: This piece was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/12/zacks-investment-research-upgrades-enanta-pharmaceuticals-enta-to-buy.html.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.